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Abstract: T he abil ity  o f  an in d iv idua l to m ount defense  
responses to infection  depend in part on the capacity  to 
produce cytokines such as in terleukin  1 (IL-1) and tumor  
necrosis factor (T N F ).  T he  specialized equ ipm ent,  labor  
intensity, and sterile practice required for the standard in 
vitro evaluation of cytokine production can make such 
evaluation impractical in some clinical situations. We 
report a m ethod for st im ulating  whole blood to produce  
cytokines that can be im plem ented in laboratories without  
tissue culture facilities and requires m in im al sample  
preparation. I L -1/3 and T N F a  production in whole blood  
samples was stimulated w ith  endotox in  and/or p h yto ­
hem agglutin in  in standard ED TA -contain ing vacuum  col­
lection tubes. After incubation , plasma was removed and  
frozen for later assay. C om parison  of  this whole blood  
m ethod with isolated m ononuclear cell cultures indicated  
a significant correlation for I L -1/3 production (r = 0 .746 ,  
P  = 0 .005). T h is  technique also produced the newly d e ­
scribed cytokine, IL-1 receptor antagonist. We conclude  
that the whole blood method is an acceptable alternative  
to isolated cell culture methods for m easuring IL-1/3 in  
situations that preclude the standard in vitro approach. J .
L eu ko c . B io l. 52: 6 8 7 -6 9 2 ;  1992.
K e y  W ords: interleukin-1 • tumor necrosis factor * interleukin-1 
receptor antagonist • whole blood assay • cytokine
INTRODUCTION
The purpose of this investigation was to develop and stan­
dardize a practical method for measuring cytokine produc­
tion by blood leukocytes from human subjects in situations 
that make the standard in vitro methods impractical, such as 
intensive care units or delivery rooms where samples need to 
be taken unexpectedly at any time of the day or night. The  
cytokines interleukin-lo' ( IL -la ) ,  IL-1 (3, and tumor necrosis 
factor oc (TNFo:) are produced by monocytes and other cells 
in response to substances such as endotoxin [1-3]. These  
cytokines mediate acute phase and inflammatory host re­
sponses that are thought to enhance host defense during in­
fection. For example, pretreatment of mice with IL-113 in­
creased survival time after administration of lethal doses of  
Pseudomonas aeruginosa [4]. However, because IL-1 ¡3 and 
TNFof mediate degradation of cartilage and bone, in­
appropriate production of these factors has been implicated 
in degenerative diseases such as rheumatoid arthritis [5]. 
Elevated levels of circulating cytokines have been reported in 
patients with septic shock [1], meningococcal disease [6], and 
other diseases associated with fever, muscle wasting, hypo­
tension, and disseminated intravascular coagulation. T hese
clinical signs can be induced by administration of cytokines 
to laboratory animals [7]. Furthermore, nutritional factors 
such as protein malnutrition [8] and dietary fatty acid intake 
[9] can influence the ability of the host to produce cytokines.
The naturally occurring, specific inhibitor of IL-1 [10, 11] 
has recently been cloned [12, 13] and renamed the IL-1 re­
ceptor antagonist (IL-lra) [reviewed in refs 14, 15]. This 
member of the IL-1 family specifically blocks IL-1 receptors 
without triggering signal transduction. Administration of 
IL-lra reduces the severity of shock and inflammation in a 
variety of animal models and is presently in clinical trials. 
The balance of production of IL-1 versus IL-lra may be an 
important determinant in the outcome of several diseases 
where IL-1 is thought to have a role. Therefore, measuring 
the relative amounts of IL-1 and IL-lra production is an im­
portant aspect of cytokine determinations from circulating 
leukocytes.
Human cytokine production is usually studied in vitro. In 
general, peripheral blood mononuclear cells (PBMCs) are 
separated by Ficoll-Hypaque gradient centrifugation, 
washed, counted, and incubated with lectins or bacterial 
toxins in an environment of controlled temperature, humid­
ity, and C 0 2 content. The process is laborious, requiring 
special attention to the preparation of reagents and culture 
vessels to prevent contamination by bacterial endotoxin. 
Blood volumes in excess of 10 ml are usually necessary to en­
sure sufficient cell yield, a requirement that can be prohibi­
tive for some pediatric studies. This study examines the 
parameters of a whole blood stimulation procedure that does 
not require specialized equipment, has a low risk of contami­
nation, and can be performed with 3 ml of blood.
MATERIALS AND METHODS 
Whole Blood Cytokine Stimulation
Venous blood samples were collected from healthy male and 
female subjects between the ages of 20 and 40 years. Blood 
was collected aseptically into pyrogen-free syringes and 
transferred into previously prepared 3 cc-draw sterile 
vacuum tubes (Becton-Dickinson, Rutherford, NJ) contain-
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ing lyophilized 4.5 mg EDTA(Na2) and 2.0 trypsin inhibi­
tory units sterile aprotonin (0.67 T IU /m l final concentra­
tion, Sigma, St. Louis, M O). Control samples contained  
100 /¿I endotoxin-free 0.154 M  sodium chloride (saline) solu­
tion and stimulated samples contained 100 /¿I of appropriate 
stimulant. Some tubes had two stimulants added, i.e., endo­
toxin [lipopolysaccharide Escherichia co/i 055:B5 (LPS) at 1, 
10, or 100 ng/ml, Sigma, St. Louis, MO] and concanavalin A 
(Con A, 5 or 50 ¿¿g/ml, Sigma, St. Louis, M O ) or phyto- 
hcmagglutinin P (PHA, 3 or 30 /¿g/ml, Difco Laboratories, 
Detroit, MI). Stimulants were added through the alcohol- 
swabbed rubber stopper of the vacuum tube with a 27 gauge 
needle attached to a 1 cc tuberculin syringe containing the 
stimulant solution. Tubes were gently inverted once to mix 
and then incubated for up to 24 h at 37°C. In pilot studies, 
cytokine (IL-1/3) yield during stationary incubation or incu­
bation on a rocking platform was compared.
After incubation, the tubes were centrifugcd at 1000 x g 
for 30 min at 4°C. The rubber stoppers were removed and 
the resulting platelet-poor plasma was pipetted into sterile 
1.5 ml microcentrifuge tubes. Samples were stored at - 7 0 ° C  
until cytokine analysis was performed. To determine appro­
priate temperature of incubation, tubes containing whole 
blood were incubated in water baths or incubators at 17, 24,
27, 30, 34, 37, and 40°C.
Mononuclear cell viability in whole blood was assessed 
after 24 h of incubation. The cells were then separated by 
Ficoll-Hypaque isolation (see below), washed twice with 
saline, then resuspended in saline with 0.05% trypan blue. 
Viability, determined per 200 cells, was >90% .
For each subject, additional blood was collected into 3 ml 
draw EDTA vacuum tubes and analyzed for complete blood 
count and differential white blood cell count by the Clinical 
Hematology Laboratory at New England Medical Center 
Hospital in order to normalize cytokine production per 106 
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Fig. 1. IL-1/3 and I NFo; production  by the whole blood m ethod  at different 
tem pera tu res  of incubation for 24 h. Whole blood was st imulated by LPS 
(10 ng/ml). T h e  da ta  represent the m ean  ± SE of five subjects. Asterisk in­
dicates significantly different from 37°C  (P  <  0.05 by ANOVA).
Statistics
Differences between means were analyzed using one-way and 
two-way analysis of variance (ANOVA). Pearson product- 
moment analysis was used to determine the correlation of  
coefficients using StatView software (Abacus Concepts, Inc., 
Calabasas CA) on a Macintosh SE/30 computer. Data were 
transformed logarithmically before ANOVA. Values are re­
ported as means with standard error of the mean (SE ) .
PBMC in vitro Stimulation
Standard in vitro cultures were prepared by established 
methods [16]. PBM Cs were isolated from heparinized blood 
by Ficoll (Sigma, St. Louis, M O )-H ypaque (Winthrop Phar­
maceutical, New York, NY) density gradient centrifugation 
and washed twice in saline. Mononuclear cells were sus­
pended at a concentration of 5 x 106 cells/ml in ultrafiltered 
[17] RPMI-1640 culture medium (Whittaker M.A. Bioprod­
ucts, Walkersville, M D ) supplemented with 2 m M  gluta­
mine, 100 U/ml of penicillin, 100 ug/ml streptomycin, and 
2% heat-inactivated human AB serum. Aliquots of 500 ul 
(2.5 x 106 cells) were added to 24-well, flat-bottomed 
microtiter plates. An equal volume of serum-free RPM I with 
or without LPS (10 ng/ml) and PH A  (30 ug/ml) was added. 
The cells were incubated at 37°C for 24 h in a humidified, 
5% C O -2 atmosphere. Supernatants were aspirated and cen­
trifuged, then cell-free supernatants were frozen at - 7 0 ° C  
until further analysis.
Cytokine assays
Plasma samples were analyzed by radioimmunoassay
for IL-1/3[2,18,19], T N F a  [20], and IL-lra [21]. Plasma 
samples intended for IL-1 ¡3 assay were lirst extracted with 
chloroform [2]. Sensitivities of the radioimmunoassays for 
each cytokine were as follows: IL-1/3, 80 pg/ml; T N F a ,  
80 pg/ml; and IL-lra, 156 pg/ml.
RESULTS 
Temperature Dependence
Incubation in the sealed vacuum-collection tubes eliminated  
the requirement of a humidified, 5% C 0 2 atmosphere. To 
investigate the minimum equipment requirements necessary 
to obtain consistent results, we determined whether a con­
trolled temperature was necessary. There was no IL-1/3 or 
T N F a  production detectable at 17°C. Whole blood cytokine 
production increased as temperature increased to 27-30°C .  
Over the physiological temperature range (30 to 40°C),  
maximal production of IL-1/3 and TNFo: after LPS stimula­
tion of whole blood was observed at 30°C (skin temperature) 
(Fig. 1). Cytokine production was attenuated at febrile tem ­
peratures (40°C) as has been shown previously in PBM C cul­
tures [22]. Because of the significant effect of temperature on 
IL-1/3 and T N F a  production, it was clear that the minimum  
equipment requirement included a constant-temperature 
water bath or air chamber. All subsequent whole blood 
studies were carried out at 37°C, nominal body core temper­
ature in health.
Additionally, there was no difference in IL-1 (3 production 
between tubes that were rocking for 24 h compared with 
tubes incubated in a stationary position (data not shown).
Dose-Response to Single and Multiple Stimuli
LPS, over a range of 1 to 100 ng/ml, stimulated significant 
dose-related increases in the production ofIL-1/3 and T N F a
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in whole blood (P  = 0.021 and 0.017, respectively). PH A
induced production of both cytokines when used alone at a 
concentration of 30 f ig/ml. In conjunction with LPS, PH A  
tended to increase cytokine production over the levels in­
duced by LPS alone, but the increases were statistically 
significant only for IL-1/3 (P  = 0.003). In this experiment, 
Con A (5 and 50 ¿ig/ml) was not a consistent stimulus for 
cytokine production, either alone or in combination with 
LPS (data not shown).
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Fig. 2. Representat ion of  dose-related response of (A) IL-1 (3 and (B) TNFcx 
production by the whole blood m ethod using combinations  of LPS and 
P H A  (incubated for 24 h at 37°C).  I he da ta  represent the mean o f  four su b ­
jects. Note different vertical scales.
C om parison  of Cytokine C oncen tra t ion  (ng/ml per 106 cells) 





3.78 ± 0.76 
2.02 ± 0 .30 i,c
8.08 ± 1.08 
0.22 ± 0.04*
"Both isolated P B M C s  (in vitro method) and stimulated whole blood 
were incubated for 24 h at 37°C. Samples from 12 subjects were tested simul­
taneously by each method.
; Significantly lower than in vitro method (P  <  0.01).
Indicates significant correlation with in vitro method (r = 0.746,
P = 0.005).
Comparison of Whole Blood and in vitro Methods
Blood samples from 12 subjects were evaluated simultane­
ously by the whole blood method and the in vitro method of 
isolated mononuclear cells. A combined stimulus of LPS 
(10 ng/ml) and PH A  (30 ug/ml) was used because IL-1/3 
production was essentially maximal at these concentrations, 
as shown in F igure  2. To facilitate comparisons, the data in 
Table 1 were normalized per 106 mononuclear cells. Mean 
IL-1/3 concentrations measured in the whole blood method 
were about half of the concentrations determined by the in 
vitro method, but the relative intersubject amounts pro­
duced were maintained, i.e., whole blood IL-1 (3 measure­
ments correlated with the results obtained by the in vitro 
method (r = 0.746, P  <  0.005) (Table 1). TNFo: concentra­
tions measured in the whole blood system were much less 
than the concentrations measured in the in vitro system 
(< 1 5 % ).  Furthermore, there was no relationship between 
whole blood concentrations and in vitro concentrations for
TNFcx (r = 0.147, P >  0.2).
The concentrations of TNFcx in whole blood samples were 
inversely related to the neutrophil count (r = -0 .677, P = 
0.016). \L -\(3  concentrations did not correlate with T N F a  
concentrations in either the whole blood or in vitro assay 
methods, consistent with previous results [23].
Time Course of Cytokine Production in the Whole Blood 
Method
Whole blood from 5 donors was stimulated with LPS 
(10 ng/ml) and PH A  (30 ug/ml) and incubated from 1 to 
24 h at 37°C (Fig. 3). TNFcx and IL-1 ¡3 were detectable after 
2 and 4 h of incubation respectively. IL-1 ¡3 reached a maxi­
m um  of 5.8 ± 2.3 ng/ml after 8 h and TNFo: a maximum 
of (0.7 ± 0.1 ng/ml) after 6 h of incubation. There was no 
significant difference between levels of IL-1 ¡3 after 8 or 24 h 
of incubation, but TNFo: levels were significantly lower after 
24 hours of incubation compared to 6 h (P  <  0.05).
The  capability to measure the newly described cytokine, 
IL-1 receptor antagonist (IL-lra), prompted us to measure 
IL-lra  in this experiment as well. Whole blood was stimu­
lated with LPS and PH A  (as above). IL-lra  was detectable 
in plasma after 3 hours of incubation and reached maximal 
concentrations of 11.8 ± 1.4 ng/ml after 10 hours (Fig. 3).
DISCUSSION
T he  purpose of this investigation was to describe a simple, 
practical method for measuring cytokine production from 
hum an  cells. The  method we have characterized uses a mini­
m um  of equipment, requires less than 3 ml of blood per
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Fig. 3. I ime coursc of IL-1/3. TNFor, and  IL - l ra  production in whole 
blood. Each time point represents the mean of 4 subjects except I L -1/3 and 
T N F a  at 6 h and  24 h where the values are the mean of  16 subjects.
person, and is reproducible. Two prevailing concerns in the 
development of this assay were to minimize sample m a n ip u ­
lation (and therefore the possibility of contamination) and to 
carry out the procedure with the simplest possible equipment.
Eskola et al. first introduced the concept of examining leu­
kocyte function in unfractionated blood samples [24]. These 
authors assessed lymphocyte proliferation measured by 
l25uridine uptake in diluted blood mixtures stimulated with 
lectins in microtiter plates. Kirschner et al. [25] used a simi­
lar cell incubation arrangement to assess production of inter­
feron. More recently, Desch et al. [26], Stricter et al. [27], 
and Schumann et al. [28] studied T N F  production in u n ­
diluted blood preparations. Yachie et al. [29] studied IL-6, 
and H am  et al. [30] studied IL-8 production in similar 
preparations. These methods involved the sterile transfer of 
blood from the collection vessel to microtiter plates or other 
tubes requiring specialized incubators and/or environments. 
T he  present report characterizes production of IL-1/3 and its 
naturally-occurring counter-regulator, IL-lra. T he  whole 
blood assay method has been modified to allow incubations 
to be carried out in virtually any surrounding  environment 
that can be maintained at a constant 37°C, with no require­
ment for control of humidity or C 0 2.
As shown in Figure 2, P H A  and LPS together resulted in 
greater stimulation of IL-1/3 production than either stimulant 
alone. At LPS concentrations greater than 10 ng/ml, there 
was no additional cytokine production due to PHA. The  
original intent for including a lectin was to induce IL-2 and 
G M -C S F  production as well. These cytokines were not de ­
tected, but this could have been due to an inability of the im ­
munoassays to detect these cytokines in plasma, ra ther than 
a lack of production. To assess IL-1 ¡3 or T N F a  production, 
LPS alone from 1 to 10 ng/ml is a sufficient stimulus. IL-1 ¡3 
and T N F a  in control samples incubated with saline only 
were uniformly nondetectable or very low, suggesting 
negligible contamination under  these conditions.
In preliminary studies with the whole blood method, the 
coefficient of variation for cytokine production from the 
same individual on different days was 30% [31]. This is simi­
lar to the intraindividual daily variation previously reported 
for peripheral blood mononuclear  cells [32].
In vitro cultures yielded 2- and 36-fold higher concentra­
tions than whole blood preparations for IL-1/3 and TNFo:, 
respectively (Table 1). There  are several reasons for this. 
First, red blood cells present in whole blood preparations 
bind lectins, thus reducing the effective concentration of the 
stimulant. Second, isolation of mononuclear cells removes 
circulating plasma factors, such as cortisol, that are physio­
logical modulators of cytokine secretion [33]. O the r  circulat­
ing factors, i.e., proteases, soluble receptors [34, 35], or 
nonspecific binding proteins, could potentially interfere with 
cytokine measurements. These factors could bind the cyto­
kines in the plasma and facilitate their internalization via 
cell-surface receptors. Soluble receptors may also bind the 
cytokines with affinities higher than that of the antibodies 
used in the RIAs. Third,  the whole blood preparation con­
tains neutrophils that are not present in the in vitro cultures. 
Neutrophils can influence cytokine production by secreting 
inhibitors [36], they may accelerate cytokine breakdown by 
releasing proteases, or they may promote clearance by b ind ­
ing and internalizing cytokines. T he  inverse correlation 
(r = -0 .677 ,  P  = 0.016) between neutrophil counts in the 
whole blood and T N F  concentrations after 24 h of incuba­
tion supports the concept that neutrophils may be an im por­
tant de term inant  of T N F a  concentrations in the whole blood 
preparation. IL-1 (3 concentrations in the whole blood 
method correlated significantly with the IL-1/3 concentra­
tions in the in vitro cultures, indicating that the whole blood 
method may be best applied to the study of this cytokine.
As a result of the recent discovery and characterization of 
IL-lra,  it is clear that a more complete assessment of IL-1 
status now requires the measurement of this antagonist. As 
shown in Figure 3, the whole blood method yielded sig­
nificant quantities of IL-lra,  similar to the magnitudes 
reported for P B M C  cultures [21]. IL -lra  production was first 
detectable after 3 h of incubation but was not maximal until
10 h. This  time course varies from that of IL-1/3, indicating 
differential regulation of these proteins. Although IL-lra  
competes with IL-1 (3 at the cell surface receptor, there is no 
cross-reactivity between IL-1/3 and IL -lra  in the RIA m ea­
surements and the IL-lra  does not bind to IL-1 ¡3 [21]. It has 
been demonstrated recently that the addition of 1% serum 
to isolated mononuclear cell cultures increased IL-lra  
production sevenfold, but had no effect on IL-1/3 production 
[21]. Likewise, pooled hum an IgG (for intravenous use) in­
duced IL-lra  production from isolated mononuclear  cells at 
concentrations as low as 1 f ig/ml. However, under these con­
ditions, IL-1/3 was not produced. Therefore, the whole blood 
method, which contains the physiologically correct concen­
tration of serum factors and IgG may be a more appropriate  
approach for the study of IL-lra. We speculate that EDTA 
in the whole blood incubations prevents IgG stimulation of 
IL -lra  but allows LPS and P H A  induction of this cytokine. 
Thus,  the whole blood stimulation of IL-lra  more closely 
reflects the in vivo production of this cytokine, compared to 
cultured mononuclear cells.
Significant near maximal concentrations of IL-1/3, T N F a ,  
and IL -lra  were observed by 6 h indicating that the whole 
blood method has the potential for use as a rapid (i.e., less 
than 1 day) method. O n  the other hand, the change in con­
centration over the next 18 h was not significant, indicating 
that overnight cultures can be done for convenience.
In summary, the whole blood method is a simple, reliable 
alternative to standard cell culture techniques for determining 
cytokine production by stimulated leukocytes. It is ideal for
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field work in that little blood is required for measurement,  it 
is not labor-intensive, samples remain sterile, and no special­
ized equipment or facilities are required. T he  potential value 
of this assay method has been demonstrated recently by Miller 
et al. [37], Using the methodology we had previously reported 
in abstract form [38], these authors were able to demonstrate  
differential IL-1/3 production in infants with perinatal infec­
tious complications, compared to healthy infants.
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